Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Uterine Leiomyoma (Uterine Fibroids) - Overview
Uterine Leiomyoma (Uterine Fibroids) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Uterine Leiomyoma (Uterine Fibroids) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Uterine Leiomyoma (Uterine Fibroids) - Companies Involved in Therapeutics Development
AbbVie Inc
Bayer AG
Context Therapeutics Inc
Daewoong Pharmaceutical Co Ltd
Endo Intertiol Plc
Eurofarma Laboratorios SA
Evestra Inc
GeneScience Pharmaceuticals Co Ltd
Immunitor Inc
Jiangsu Hengrui Medicine Co Ltd
Kissei Pharmaceutical Co Ltd
Livzon Pharmaceutical Group Co Ltd
Luye Pharma Group Ltd
Richter Gedeon Nyrt
TiumBio Co Ltd
Uterine Leiomyoma (Uterine Fibroids) - Drug Profiles
collagese clostridium histolyticum - Drug Profile
Product Description
Mechanism Of Action
History of Events
CTX-30916 - Drug Profile
Product Description
Mechanism Of Action
Drug to Agonize Progesterone Receptor for Uterine Fibroids - Drug Profile
Product Description
Mechanism Of Action
DWJ-1483 - Drug Profile
Product Description
Mechanism Of Action
EC-313 - Drug Profile
Product Description
Mechanism Of Action
elagolix sodium - Drug Profile
Product Description
Mechanism Of Action
History of Events
goserelin acetate - Drug Profile
Product Description
Mechanism Of Action
leuprolide acetate - Drug Profile
Product Description
Mechanism Of Action
linzagolix choline - Drug Profile
Product Description
Mechanism Of Action
History of Events
NCE-403 - Drug Profile
Product Description
Mechanism Of Action
History of Events
SHR-7280 - Drug Profile
Product Description
Mechanism Of Action
History of Events
triptorelin acetate ER - Drug Profile
Product Description
Mechanism Of Action
triptorelin acetate SR - Drug Profile
Product Description
Mechanism Of Action
ulipristal acetate - Drug Profile
Product Description
Mechanism Of Action
History of Events
V3-Myoma - Drug Profile
Product Description
Mechanism Of Action
History of Events
vilaprisan - Drug Profile
Product Description
Mechanism Of Action
History of Events
Uterine Leiomyoma (Uterine Fibroids) - Dormant Projects
Uterine Leiomyoma (Uterine Fibroids) - Discontinued Products
Uterine Leiomyoma (Uterine Fibroids) - Product Development Milestones
Featured News & Press Releases
Feb 04, 2022: ObsEva provides update on EU marketing authorisation process for linzagolix, an oral GnRH antagonist, for the treatment of uterine fibroids
Dec 17, 2021: ObsEva Announces Positive CHMP Opinion for Linzagolix, an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids
Dec 10, 2021: ObsEva hosts symposium and presents clinical data on oral GnRH antagonist Linzagolix at SEUD Congress 2021
Dec 02, 2021: ObsEva announces symposium and presentation of clinical data on oral GnRH antagonist Linzagolix at SEUD Congress 2021
Nov 22, 2021: Obseva announces U.S. FDA acceptance of new drug application for Linzagolix
Oct 20, 2021: ObsEva presents clinical data on oral GnRH antagonist Linzagolix for the treatment of uterine fibroids at ASRM 2021 Scientific Congress & Expo
Oct 19, 2021: ObsEva announces presentation of clinical data on oral GnRH antagonist linzagolix at ASRM 2021 Scientific Congress & Expo
Sep 15, 2021: ObsEva announces submission of New Drug Application to U.S. FDA for Linzagolix for the treatment of Uterine Fibroids
Jun 30, 2021: ObsEva presents clinical data on open-label pilot study of Yselty (linzagolix) for the treatment of severe adenomyosis at ESHRE Virtual 37th Annual Meeting
Jun 24, 2021: ObsEva to present data on Yselty (linzagolix) at ESHRE Virtual 37th Annual Meeting
May 20, 2021: ObsEva announces fil results from the phase 3 PRIMROSE program of Yselty (linzagolix) for the treatment of uterine fibroids
May 04, 2021: ObsEva announces enrollment completion of linzagolix phase 3 EDELWEISS 3 trial for patients with moderate to severe endometriosis-associated pain
Apr 30, 2021: ObsEva presents posters at the ACOG Annual Clinical and Scientific Virtual Meeting April 30 - May 2, 2021
Apr 27, 2021: ObsEva initiates PRIMROSE 3 bone mineral density follow-up study in PRIMROSE 1 and PRIMROSE 2 trial participants
Feb 18, 2021: Ulipristal acetate 5mg (Esmya): further restrictions due to risk of serious liver injury
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development for Uterine Leiomyoma (Uterine Fibroids), 2022
Number of Products under Development by Companies, 2022
Number of Products by Targets, 2022
Number of Products by Stage and Targets, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022

List of Tables

List of Tables
Number of Products under Development for Uterine Leiomyoma (Uterine Fibroids), 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Uterine Leiomyoma (Uterine Fibroids) - Pipeline by AbbVie Inc, 2022
Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Bayer AG, 2022
Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Context Therapeutics Inc, 2022
Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Daewoong Pharmaceutical Co Ltd, 2022
Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Endo International Plc, 2022
Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Eurofarma Laboratorios SA, 2022
Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Evestra Inc, 2022
Uterine Leiomyoma (Uterine Fibroids) - Pipeline by GeneScience Pharmaceuticals Co Ltd, 2022
Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Immunitor Inc, 2022
Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2022
Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Kissei Pharmaceutical Co Ltd, 2022
Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Livzon Pharmaceutical Group Co Ltd, 2022
Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Luye Pharma Group Ltd, 2022
Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Richter Gedeon Nyrt, 2022
Uterine Leiomyoma (Uterine Fibroids) - Pipeline by TiumBio Co Ltd, 2022
Uterine Leiomyoma (Uterine Fibroids) - Dormant Projects, 2022
Uterine Leiomyoma (Uterine Fibroids) - Dormant Projects, 2022 (Contd..1)
Uterine Leiomyoma (Uterine Fibroids) - Discontinued Products, 2022